TNF and ductal breast carcinoma in situ: As in the DCIS and IDC-no-relapse groups, the incidence of CCL2 and CCL5 in the IDC-with-relapse group remained at the level of 50-65%; however, the incidence of TNFα and IL-1β expression in the IDC-with-relapse group was increased to 85-90% (Figure 2).